Targacept Backpedals on TC-6987 After Data Analysis Error

Washington Drug Letter
Targacept’s asthma candidate TC-6987 met only one of its co-primary endpoints in a Phase II study, the company revealed April 10, placing the asthma indication on shakier ground than previously reported.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00